Treace Medical Concepts, Inc. ((TMCI)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Treace Medical Concepts’ latest earnings call painted a cautiously mixed picture for investors. Management highlighted solid operational progress, including portfolio expansion, growing surgeon adoption and sharply lower cash burn, alongside fresh liquidity. Yet these gains were balanced by weaker near‑term revenue trends, a larger Q4 net loss and guidance that points to little or no growth in 2026.
Expanding Portfolio Targets Larger Bunion and Foot Market
Treace rolled out three new bunion systems in 2025 — Nanoplasty, Percuplasty 3D MIS and SpeedMTP — plus incremental Lapiplasty innovations such as Micro‑Lapiplasty and upcoming Lapiplasty Lightning and Speed TMT. Management believes these launches meaningfully expand its addressable market and is planning two more 2026 introductions, SuperBite screws and Speed XM, that could add about $300 million of TAM.
Surgeon Adoption Builds with Broader System Utilization
The company emphasized strong surgeon engagement, with its active base rising from about 1,300 in 2020 to more than 3,300 in 2025. By Q4 2025, over a quarter of these surgeons had already incorporated at least one of the three new systems just a few quarters after launch, helping push Q4 procedure growth above the mid‑single‑digit pace seen in Q3.
Adjusted EBITDA and Cash Burn Show Meaningful Progress
On profitability metrics, Treace showed notable year‑over‑year improvement despite revenue pressure. Full‑year 2025 adjusted EBITDA loss narrowed to $3.9 million from $11.0 million in 2024, while cash used dropped to $27.3 million from $50.5 million, marking a 64% improvement in adjusted EBITDA and a 46% reduction in cash burn.
Margins Hold Firm as Quarterly EBITDA Turns Positive
Gross margin remained a key bright spot, with Q4 2025 gross margin at 80.6%, essentially flat with the prior‑year quarter’s 80.7%. Treace also delivered positive adjusted EBITDA on a quarterly basis, posting $6.2 million in Q4 2025, underscoring the business’s attractive unit economics even as top‑line growth slowed.
Liquidity Bolstered by Cash Reserves and New Credit Facility
The balance sheet was another area of focus, with Treace reporting $48.4 million in cash, cash equivalents and marketable securities at year‑end 2025. In addition, the company obtained a new credit facility that provides up to $115 million of extra liquidity, subject to conditions, giving management additional flexibility to fund product launches and targeted commercial investments.
2026 Profitability Plan Emphasizes Efficiency and Cash Control
Looking to 2026 operations, management aims to roughly halve cash burn while continuing to invest in growth initiatives. The company guided to a full‑year adjusted EBITDA loss between $4 million and $6 million, roughly in line with 2025, as it balances expenses for new products and select sales hires against continued cost discipline and efficiency efforts.
Revenue Declines Underscore Near‑Term Growth Challenges
Despite progress on costs and products, Q4 2025 revenue fell 9% year over year to $62.5 million, highlighting near‑term headwinds. Management pointed to a mix shift toward newer, lower‑priced offerings as a key driver of the decline, signaling that volume gains are not yet fully offsetting lower average selling prices.
GAAP Net Loss Widens Sharply in the Fourth Quarter
On a GAAP basis, profitability deteriorated, with Q4 2025 net loss expanding to $9.4 million, or $0.15 per share, versus a $0.5 million loss, or $0.01 per share, a year earlier. The jump in quarterly losses underscores the gap between adjusted profitability and reported earnings as the company absorbs higher costs and one‑time items.
Quarterly Adjusted EBITDA Slips Against Tough Comparison
Even on an adjusted basis, Q4 profitability softened compared with the prior year’s strong quarter. Adjusted EBITDA for Q4 2025 came in at $6.2 million versus $11.1 million in Q4 2024, reflecting a significant year‑over‑year step‑down that highlights the impact of revenue pressure and ongoing investment spending.
Product Mix and Macro Softness Weigh on Top Line
Management repeatedly cited the drag from a shift toward lower‑priced systems introduced in 2025, which is compressing average revenue per procedure. Broader weakness in elective foot and ankle surgeries added another layer of pressure, suggesting that macro factors and mix dynamics will remain headwinds until higher‑priced launches scale.
Operating Expenses Elevated by Restructuring and Litigation
Operating costs stayed high, totaling $56.3 million in Q4 2025 compared with $55.7 million a year earlier. The increase reflected restructuring charges, higher litigation expenses and heavier 2025 capital spending on instrumentation, which management expects to moderate in 2026 as those investments taper.
Guidance Signals Flat to Down 2026 with Back‑Half Recovery
For 2026, Treace guided revenue to a range of $200 million to $212 million, implying between a 6% decline and flat growth versus 2025, with declines expected to continue until the seasonally strong fourth quarter and Q1 revenue projected to fall about 27% from Q4 2025. The company anticipates a full‑year adjusted EBITDA loss of $4 million to $6 million and plans to cut cash usage roughly in half, expecting stronger performance later in 2026 as new higher‑priced offerings gain traction.
Treace’s earnings call presented a company at an inflection point, pairing strong surgeon uptake, resilient margins and improved cash discipline with softer revenue and widening GAAP losses. For investors, the story hinges on whether the expanding product portfolio and back‑half 2026 expectations can overcome current mix and macro headwinds to restore sustainable top‑line growth.